Table 2.
Clinicopathological characteristics of patients at baseline
| Characteristics | All patients (n = 135) |
Subtypes | P-value | |||
|---|---|---|---|---|---|---|
| ASCL1 dominant(n = 73) | NEUROD1 dominant(n = 27) | POU2F3(n = 10) | Inflamed(n = 25) | |||
| Sex | 0.39 | |||||
| Male | 120(88.9%) | 65(89.0%) | 22(81.5%) | 10(100.0%) | 23(92.0%) | |
| Female | 15(11.1%) | 8(11.0%) | 5(18.5%) | 0(0.0%) | 2(8.0%) | |
| Median age, years | 65.0(43–87) | 65.8(49–87) | 63.2(54–74) | 72.5(57–87) | 62.0(43–75) | 0.48 |
| Smoking status | 0.32 | |||||
| Never smoker | 20(14.8%) | 13(17.8%) | 5(18.5%) | 0(0.0%) | 2(8.0%) | |
| Smoker | 115(85.2%) | 60(82.2%) | 22(81.5%) | 10(100.0%) | 23(92.0%) | |
| Disease stage | 0.37 | |||||
| IIIb-IIIc | 27(20.0%) | 13(17.8%) | 5(18.5%) | 1(10.0%) | 8(32.0%) | |
| IV | 108(80.0%) | 60(82.2%) | 22(81.5%) | 9(90.0%) | 17(68.0%) | |
| CNS metastases | 0.71 | |||||
| No | 116(85.9%) | 64(87.7%) | 24(88.9%) | 8(80.0%) | 20(80.0%) | |
| Yes | 19(14.1%) | 9(12.3%) | 3(11.1%) | 2(20.0%) | 5(20.0%) | |
| Liver metastases | 0.20 | |||||
| No | 104(77.0%) | 53(72.6%) | 20(74.1%) | 10(100.0%) | 21(84.0%) | |
| Yes | 31(23.0%) | 20(27.4%) | 7(25.9%) | 0(0.0%) | 4(16.0%) | |
| Bone metastases | 0.32 | |||||
| No | 95(70.4%) | 52(71.2%) | 16(59.3%) | 9(90.0%) | 18(72.0%) | |
| Yes | 40(29.6%) | 21(28.8%) | 11(40.7%) | 1(10.0%) | 7(28.0%) | |
| Pleural metastases | 0.87 | |||||
| No | 107(79.3%) | 56(76.7%) | 22(81.5%) | 8(80.0%) | 21(84.0%) | |
| Yes | 28(20.7%) | 17(23.3%) | 5(18.5%) | 2(20.0%) | 4(16.0%) | |
| Immunotherapy regimens | 0.73 | |||||
| Duvaluzuma plus platinum-based chemotherapy | 92(68.2%) | 50(68.5%) | 16(59.3%) | 8(80.0%) | 18(72.0%) | |
| Atezolizumab plus platinum-based chemotherapy | 28(20.7%) | 17(23.3%) | 6(22.2%) | 1(10.0%) | 4(16.0%) | |
| Serplulimab plus platinum-based chemotherapy | 15(11.1%) | 6(8.2%) | 5(18.5%) | 1(10.0%) | 3(12.0%) | |
CNS: Central nervous system